|
|
|
 |
| Location: Home -
Products - Active Pharma Ingredients(API) - Antivirals
|
Raltegravir(MK-0518)
| Catalogue No. : |
C14081 |
| Product Name: |
Raltegravir(MK-0518) |
| Synonym: |
MK-0518;Isentress |
| Chemical Name: |
N-(2-(4-(4-Fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide; N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide |
| CAS No. : |
518048-05-0 |
| Structure : |
|
| Molecular Formula: |
C20H21FN6O5 |
| Molecular Weight: |
444.15 |
| Purity: |
>99% |
| Usage: |
Raltegravir is a potent HIV-1 integrase inhibitor. Raltegravir sensitizes S217Q PFV IN to the same extent as the WT enzyme. Raltegravir is potently active against HIV-1 in vitro. Raltegravir is also active against HIV-2 in CEMx174 cells. Raltegravir weakly inhibits hepatic cytochrome P450 activity. Raltegravir effectively attenuates viral replication. Raltegravir efficiently inhibits SIVmac251 replication in acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
